Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

IMAX vs RGC vs CNK vs NUVB

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
IMAX
IMAX Corporation

Entertainment

Communication ServicesNYSE • CA
Market Cap$1.92B
5Y Perf.+120.8%
RGC
Regencell Bioscience Holdings Limited

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • HK
Market Cap$15.56B
5Y Perf.+12941.9%
CNK
Cinemark Holdings, Inc.

Entertainment

Communication ServicesNYSE • US
Market Cap$3.21B
5Y Perf.+76.9%
NUVB
Nuvation Bio Inc.

Biotechnology

HealthcareNYSE • US
Market Cap$1.67B
5Y Perf.-44.2%

IMAX vs RGC vs CNK vs NUVB — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
IMAX logoIMAX
RGC logoRGC
CNK logoCNK
NUVB logoNUVB
IndustryEntertainmentDrug Manufacturers - Specialty & GenericEntertainmentBiotechnology
Market Cap$1.92B$15.56B$3.21B$1.67B
Revenue (TTM)$405M$0.00$3.12B$143M
Net Income (TTM)$43M$-5M$138M$-146M
Gross Margin58.1%40.7%91.6%
Operating Margin21.4%11.0%-105.0%
Forward P/E21.1x13.0x
Total Debt$297M$86K$3.78B$10M
Cash & Equiv.$151M$3M$344M$164M

IMAX vs RGC vs CNK vs NUVBLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

IMAX
RGC
CNK
NUVB
StockJul 21May 26Return
IMAX Corporation (IMAX)100220.8+120.8%
Regencell Bioscienc… (RGC)10013041.9+12941.9%
Cinemark Holdings, … (CNK)100176.9+76.9%
Nuvation Bio Inc. (NUVB)10055.8-44.2%

Price return only. Dividends and distributions are not included.

Quick Verdict: IMAX vs RGC vs CNK vs NUVB

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CNK leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. IMAX Corporation is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. RGC and NUVB also each lead in at least one category. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
IMAX
IMAX Corporation
The Income Pick

IMAX is the #2 pick in this set and the best alternative if income & stability is your priority.

  • Dividend streak 1 yrs, beta 0.43
  • 10.7% margin vs NUVB's -102.1%
  • 4.9% ROA vs RGC's -60.2%, ROIC 12.7% vs -43.8%
Best for: income & stability
RGC
Regencell Bioscience Holdings Limited
The Long-Run Compounder

RGC is the clearest fit if your priority is long-term compounding and sleep-well-at-night.

  • 119.3% 10Y total return vs IMAX's 8.9%
  • Lower volatility, beta 0.72, Low D/E 1.0%, current ratio 41.92x
  • Beta 0.72, current ratio 41.92x
  • +5.3% vs CNK's -10.7%
Best for: long-term compounding and sleep-well-at-night
CNK
Cinemark Holdings, Inc.
The Value Play

CNK carries the broadest edge in this set and is the clearest fit for value and stability.

  • Better valuation composite
  • Beta 0.22 vs NUVB's 2.04
  • 1.1% yield; the other 3 pay no meaningful dividend
Best for: value and stability
NUVB
Nuvation Bio Inc.
The Growth Play

NUVB is the clearest fit if your priority is growth exposure.

  • Rev growth 7.0%, EPS growth 71.6%
  • 7.0% revenue growth vs CNK's 2.1%
Best for: growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthNUVB logoNUVB7.0% revenue growth vs CNK's 2.1%
ValueCNK logoCNKBetter valuation composite
Quality / MarginsIMAX logoIMAX10.7% margin vs NUVB's -102.1%
Stability / SafetyCNK logoCNKBeta 0.22 vs NUVB's 2.04
DividendsCNK logoCNK1.1% yield; the other 3 pay no meaningful dividend
Momentum (1Y)RGC logoRGC+5.3% vs CNK's -10.7%
Efficiency (ROA)IMAX logoIMAX4.9% ROA vs RGC's -60.2%, ROIC 12.7% vs -43.8%

IMAX vs RGC vs CNK vs NUVB — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

IMAXIMAX Corporation
FY 2025
Image Enhancement And Maintenance Services
54.7%$218M
Technology Sales
24.7%$98M
Technology Rentals
20.6%$82M
RGCRegencell Bioscience Holdings Limited

Segment breakdown not available.

CNKCinemark Holdings, Inc.
FY 2025
Admissions Revenue
49.6%$1.5B
Concessions
39.4%$1.2B
Other Revenues
11.0%$343M
NUVBNuvation Bio Inc.
FY 2025
License
60.8%$38M
Product
39.2%$25M

IMAX vs RGC vs CNK vs NUVB — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLIMAXLAGGINGNUVB

Income & Cash Flow (Last 12 Months)

Evenly matched — IMAX and NUVB each lead in 3 of 6 comparable metrics.

CNK and RGC operate at a comparable scale, with $3.1B and $0 in trailing revenue. IMAX is the more profitable business, keeping 10.7% of every revenue dollar as net income compared to NUVB's -102.1%. On growth, NUVB holds the edge at +26.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricIMAX logoIMAXIMAX CorporationRGC logoRGCRegencell Bioscie…CNK logoCNKCinemark Holdings…NUVB logoNUVBNuvation Bio Inc.
RevenueTrailing 12 months$405M$0$3.1B$143M
EBITDAEarnings before interest/tax$150M-$4M$545M-$145M
Net IncomeAfter-tax profit$43M-$5M$138M-$146M
Free Cash FlowCash after capex$115M-$7M$177M-$126M
Gross MarginGross profit ÷ Revenue+58.1%+40.7%+91.6%
Operating MarginEBIT ÷ Revenue+21.4%+11.0%-105.0%
Net MarginNet income ÷ Revenue+10.7%+4.4%-102.1%
FCF MarginFCF ÷ Revenue+28.5%+5.7%-88.1%
Rev. Growth (YoY)Latest quarter vs prior year-6.1%-4.7%+26.0%
EPS Growth (YoY)Latest quarter vs prior year+65.5%-18.2%+106.3%
Evenly matched — IMAX and NUVB each lead in 3 of 6 comparable metrics.

Valuation Metrics

CNK leads this category, winning 3 of 6 comparable metrics.

At 26.4x trailing earnings, CNK trades at a 53% valuation discount to IMAX's 56.6x P/E. On an enterprise value basis, CNK's 12.2x EV/EBITDA is more attractive than IMAX's 13.1x.

MetricIMAX logoIMAXIMAX CorporationRGC logoRGCRegencell Bioscie…CNK logoCNKCinemark Holdings…NUVB logoNUVBNuvation Bio Inc.
Market CapShares × price$1.9B$15.6B$3.2B$1.7B
Enterprise ValueMkt cap + debt − cash$2.1B$15.6B$6.6B$1.5B
Trailing P/EPrice ÷ TTM EPS56.56x-3617.24x26.42x-8.03x
Forward P/EPrice ÷ next-FY EPS est.21.15x12.97x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple13.10x12.23x
Price / SalesMarket cap ÷ Revenue4.69x1.03x26.61x
Price / BookPrice ÷ Book value/share4.63x1893.39x8.92x5.38x
Price / FCFMarket cap ÷ FCF16.18x18.11x
CNK leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

IMAX leads this category, winning 5 of 9 comparable metrics.

CNK delivers a 25.4% return on equity — every $100 of shareholder capital generates $25 in annual profit, vs $-67 for RGC. RGC carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to CNK's 9.14x. On the Piotroski fundamental quality scale (0–9), IMAX scores 7/9 vs NUVB's 4/9, reflecting strong financial health.

MetricIMAX logoIMAXIMAX CorporationRGC logoRGCRegencell Bioscie…CNK logoCNKCinemark Holdings…NUVB logoNUVBNuvation Bio Inc.
ROE (TTM)Return on equity+10.8%-67.0%+25.4%-44.1%
ROA (TTM)Return on assets+4.9%-60.2%+3.0%-23.8%
ROICReturn on invested capital+12.7%-43.8%+7.5%-54.3%
ROCEReturn on capital employed+14.5%-46.8%+9.3%-42.8%
Piotroski ScoreFundamental quality 0–97454
Debt / EquityFinancial leverage0.70x0.01x9.14x0.03x
Net DebtTotal debt minus cash$146M-$3M$3.4B-$154M
Cash & Equiv.Liquid assets$151M$3M$344M$164M
Total DebtShort + long-term debt$297M$85,741$3.8B$10M
Interest CoverageEBIT ÷ Interest expense21.15x1.89x-162.11x
IMAX leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

RGC leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in RGC five years ago would be worth $1,138,979 today (with dividends reinvested), compared to $4,173 for NUVB. Over the past 12 months, RGC leads with a +529.4% total return vs CNK's -10.7%. The 3-year compound annual growth rate (CAGR) favors RGC at 2.6% vs CNK's 19.6% — a key indicator of consistent wealth creation.

MetricIMAX logoIMAXIMAX CorporationRGC logoRGCRegencell Bioscie…CNK logoCNKCinemark Holdings…NUVB logoNUVBNuvation Bio Inc.
YTD ReturnYear-to-date-1.1%+53.2%+17.2%-43.8%
1-Year ReturnPast 12 months+38.9%+529.4%-10.7%+136.3%
3-Year ReturnCumulative with dividends+79.5%+4525.9%+71.0%+197.5%
5-Year ReturnCumulative with dividends+70.3%+11289.8%+29.3%-58.3%
10-Year ReturnCumulative with dividends+8.9%+11926.8%-6.6%-51.8%
CAGR (3Y)Annualised 3-year return+21.5%+2.6%+19.6%+43.8%
RGC leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — IMAX and CNK each lead in 1 of 2 comparable metrics.

CNK is the less volatile stock with a 0.22 beta — it tends to amplify market swings less than NUVB's 2.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMAX currently trades 82.6% from its 52-week high vs RGC's 37.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricIMAX logoIMAXIMAX CorporationRGC logoRGCRegencell Bioscie…CNK logoCNKCinemark Holdings…NUVB logoNUVBNuvation Bio Inc.
Beta (5Y)Sensitivity to S&P 5000.43x0.72x0.22x2.04x
52-Week HighHighest price in past year$43.16$83.60$34.01$9.75
52-Week LowLowest price in past year$24.20$3.93$21.60$1.57
% of 52W HighCurrent price vs 52-week peak+82.6%+37.6%+80.8%+49.4%
RSI (14)Momentum oscillator 0–10042.447.543.759.1
Avg Volume (50D)Average daily shares traded1.1M139K2.1M4.3M
Evenly matched — IMAX and CNK each lead in 1 of 2 comparable metrics.

Analyst Outlook

IMAX leads this category, winning 1 of 1 comparable metric.

Analyst consensus: IMAX as "Buy", RGC as "Hold", CNK as "Buy", NUVB as "Buy". Consensus price targets imply 157.3% upside for NUVB (target: $12) vs 15.2% for CNK (target: $32). CNK is the only dividend payer here at 1.05% yield — a key consideration for income-focused portfolios.

MetricIMAX logoIMAXIMAX CorporationRGC logoRGCRegencell Bioscie…CNK logoCNKCinemark Holdings…NUVB logoNUVBNuvation Bio Inc.
Analyst RatingConsensus buy/hold/sellBuyHoldBuyBuy
Price TargetConsensus 12-month target$43.00$31.67$12.40
# AnalystsCovering analysts254319
Dividend YieldAnnual dividend ÷ price+1.1%
Dividend StreakConsecutive years of raises10
Dividend / ShareAnnual DPS$0.29
Buyback YieldShare repurchases ÷ mkt cap+0.1%0.0%+8.6%0.0%
IMAX leads this category, winning 1 of 1 comparable metric.
Key Takeaway

IMAX leads in 2 of 6 categories (Profitability & Efficiency, Analyst Outlook). CNK leads in 1 (Valuation Metrics). 2 tied.

Best OverallIMAX Corporation (IMAX)Leads 2 of 6 categories
Loading custom metrics...

IMAX vs RGC vs CNK vs NUVB: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is IMAX or RGC or CNK or NUVB a better buy right now?

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus 2. 1% for Cinemark Holdings, Inc. (CNK). Cinemark Holdings, Inc. (CNK) offers the better valuation at 26. 4x trailing P/E (13. 0x forward), making it the more compelling value choice. Analysts rate IMAX Corporation (IMAX) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — IMAX or RGC or CNK or NUVB?

On trailing P/E, Cinemark Holdings, Inc.

(CNK) is the cheapest at 26. 4x versus IMAX Corporation at 56. 6x. On forward P/E, Cinemark Holdings, Inc. is actually cheaper at 13. 0x.

03

Which is the better long-term investment — IMAX or RGC or CNK or NUVB?

Over the past 5 years, Regencell Bioscience Holdings Limited (RGC) delivered a total return of +112.

9%, compared to -58. 3% for Nuvation Bio Inc. (NUVB). Over 10 years, the gap is even starker: RGC returned +119. 3% versus NUVB's -51. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — IMAX or RGC or CNK or NUVB?

By beta (market sensitivity over 5 years), Cinemark Holdings, Inc.

(CNK) is the lower-risk stock at 0. 22β versus Nuvation Bio Inc. 's 2. 04β — meaning NUVB is approximately 836% more volatile than CNK relative to the S&P 500. On balance sheet safety, Regencell Bioscience Holdings Limited (RGC) carries a lower debt/equity ratio of 1% versus 9% for Cinemark Holdings, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — IMAX or RGC or CNK or NUVB?

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus 2. 1% for Cinemark Holdings, Inc. (CNK). On earnings-per-share growth, the picture is similar: Nuvation Bio Inc. grew EPS 71. 6% year-over-year, compared to -49. 5% for Cinemark Holdings, Inc.. Over a 3-year CAGR, IMAX leads at 10. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — IMAX or RGC or CNK or NUVB?

IMAX Corporation (IMAX) is the more profitable company, earning 8.

5% net margin versus -325. 3% for Nuvation Bio Inc. — meaning it keeps 8. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMAX leads at 23. 3% versus -338. 7% for NUVB. At the gross margin level — before operating expenses — NUVB leads at 86. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is IMAX or RGC or CNK or NUVB more undervalued right now?

On forward earnings alone, Cinemark Holdings, Inc.

(CNK) trades at 13. 0x forward P/E versus 21. 1x for IMAX Corporation — 8. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NUVB: 157. 3% to $12. 40.

08

Which pays a better dividend — IMAX or RGC or CNK or NUVB?

In this comparison, CNK (1.

1% yield) pays a dividend. IMAX, RGC, NUVB do not pay a meaningful dividend and should not be held primarily for income.

09

Is IMAX or RGC or CNK or NUVB better for a retirement portfolio?

For long-horizon retirement investors, Cinemark Holdings, Inc.

(CNK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 22), 1. 1% yield). Nuvation Bio Inc. (NUVB) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CNK: -6. 6%, NUVB: -51. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between IMAX and RGC and CNK and NUVB?

These companies operate in different sectors (IMAX (Communication Services) and RGC (Healthcare) and CNK (Communication Services) and NUVB (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: IMAX is a small-cap high-growth stock; RGC is a mid-cap quality compounder stock; CNK is a small-cap quality compounder stock; NUVB is a small-cap high-growth stock. CNK pays a dividend while IMAX, RGC, NUVB do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

IMAX

Quality Business

  • Sector: Communication Services
  • Market Cap > $100B
  • Net Margin > 6%
Run This Screen
Stocks Like

RGC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

CNK

Stable Dividend Mega-Cap

  • Sector: Communication Services
  • Market Cap > $100B
  • Gross Margin > 24%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

NUVB

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 1299%
  • Gross Margin > 54%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.